

# Subject Index

## A

Acetaldehyde, 912  
Acetoacetyl-CoA synthetase, 50  
Acinar autoantibodies, 347  
Activated T-lymphocytes, 507, 792  
Acyl-CoA:cholesterol acyltransferase, 342  
Adenine nucleotides, 629  
Adenosine  
  deaminase, 629  
  myocardial insulin responsiveness, 842  
Adipocytes, 912, 1618  
Adjuvants, synergistic effects, 112  
Adoptive immunotherapy, 1305  
 $\beta$ -Adrenergic receptor, 1181, 1386  
Aggregating agents, 780, 1652  
Aging  
  collagen browning and cross-linking, 867  
  glucose intolerance, 119  
Alanine production, 237, 1559  
Aldose reductase  
  inhibition, 359, 471, 558, 969, 1324  
  neuropathy pathogenesis, 688  
  retinopathy, 1658  
  substance P, 488  
Allotransplantation  
  pancreatic endocrine cells, 383  
  pancreatic islet cells, 1129  
Alloxan, 1015  
  -induced diabetic rats, 1173, 1340  
American Indians, 622  
Amino acid  
  glucogenic, 237  
  glycosylated, 1144  
  heart balance, 943  
  infusion effects, 1365  
Amylase, 1173  
Angiopathy, 1260  
Angiotensin II, 1064  
Antigens  
  class I, 209, 362, 796, 1411  
  class II, 209, 482, 796, 1373, 1637  
  islet cells, 1137  
  64,000-*M*<sub>r</sub>, 1419  
Antithrombin III, 1103  
Anti-asialo-GM1 antibody, 838  
Anti-immunoglobulin antibodies, 462  
Apolipoprotein B, 1234  
Arachidonate, enhanced availability, 429  
Arachidonic acid  
  activator of protein kinase C, 4, 1453  
  metabolites, 992  
Arginine  
   $\beta$ -endorphin effects, 1265  
  insulin response, 723

Ascorbic acid, 359  
Atherosclerosis, 832, 1380  
ATP  
  cerebral metabolism, 760  
  -sensitive K<sup>+</sup> channel, 495, 847  
Autoimmune thyroid disease, 317  
Autoimmunity, 257, 520, 1419  
  cell-mediated, 873  
Autonomic nervous system  
  abnormality, 446  
  CSII effect on, 452  
Axonal transport of substance P, 488

## B

Bacitracin, 800  
Bacterial killing, 544  
Basement membranes, 532  
BioBreeding (BB) rat. See Rats  
BB/W rats. See Rats  
Biosynthesis, HIT cells, 160, 1509  
Blood flow  
  detection of vascular dysfunction, 292  
  subcutaneous and insulin absorption, 694  
  thermoregulation, 961  
Blood withdrawal, 327  
Bone  
  calcium, 702  
   $\gamma$ -carboxyglutamic acid-containing protein, 702  
  cell metabolism, 33  
  formation and collagen production, 371  
  hydroxyproline, 702  
  marrow transplantation, 520  
  mineral content, 8  
Breast-feeding, 1625  
Brittle diabetes, 81  
Butylated hydroxytoluene, 1505

## C

Calcium  
  antagonists, 936  
  arachidonic acid effect, 1453  
  cellular homeostasis alterations, 13  
  phosphoinositide hydrolysis, 1478  
  voltage-dependent channels, 847  
cAMP  
  binding to protein kinase, 857  
  phosphodiesterase activity, 717  
Canadian children, 1096  
Carbohydrate storage, 303

## Cardiac

  function, 851  
    L-carnitine effect, 1358  
    myo-inositol effect, 1542  
  ultrastructure, 936  
  unresponsiveness, 1181  
Cardiac metabolism, 936  
Cardiomyopathy, 936, 1168  
L-Carnitine, 1358  
Cataractogenesis, 1505  
Catecholamines  
  hydrochloride salt effect, 540  
  low-density lipoprotein-receptor activity, effect on, 1386  
 $\beta$ -Cell, 260  
  activation, 137  
  cholecystokinin effects, 1432  
  coupling increased, 908  
  destruction  
    interleukin 1, 916  
    markers, 99  
    marrow transfer, 252  
    prevention of, 930  
    progression from insulinitis, 1108  
    reovirus infection, 362  
  epinephrine effects, 65  
  function assessment, 377  
  glucose-induced depolarization, 495  
  glucose-induced diabetes, 600  
  granules, 194  
  growth, 232  
  insulin secretory responses altered, 137, 217  
  interleukin 1 effects, 1311  
  loss indicator, 723  
  morphology, 89  
  pancreatic  
    ATP-sensitive K<sup>+</sup> channels, 495  
    glucose metabolism control, 1524  
    secretory capacity, 81  
    sulfonylureas, 1090  
  parotidectomy, effect of, 441  
  polarity, 616  
  sensitivity, 223  
  streptozocin-induced toxicity, 213  
  survival, predictors of, 920  
Cell birth rate, 232  
Central nervous system and clonidine, 44  
Cerebral metabolism, 760  
Cheiroarthropathy, reduced lung volumes, 829  
Cholecystokinin, 13, 1432  
Cholesterol  
  absorption, 342  
  ester synthesis, 550  
  insulin deficiency, 1151  
  intensive treatment effect, 393

## DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1–136

February, 137–255

March, 257–365

April, 367–493

May, 495–665

June, 667–845

July, 847–1004

August, 1005–1156

September, 1157–1309

October, 1311–1448

November, 1449–1590

December, 1591–1726

This index covers all reading matter in Volume 37 of Diabetes except abstracts of papers presented at the 48th Annual Meeting of the American Diabetes Association.

**SUBJECT INDEX 1988**

Citric acid cycle, 89  
 Clamps  
   euglycemic, 303, 780, 787, 885  
   euglycemic-hyperinsulinemic, 842, 1212, 1684  
   glucose, 1025  
   hyperglycemic, 1351  
 Clonidine and hyperglycemia, 44  
 Coxsackievirus B4 infection, 1419  
 Collagen  
   ascorbic acid, 359  
   browning and aging, 867  
   decreased production, 371  
   glycosylated, 1144  
   mesangial sclerosis, 1695  
   type IV and basement membranes, 532  
 Complications  
   basement membranes, 532  
   vascular dysfunction, 292  
 Connective tissue, reduced lung volumes, 829  
 Continuous subcutaneous insulin infusion (CSII)  
   autonomic and somatosensory nerve function, 452  
   counterregulatory hormone responses, 526  
 Cori cycle, 154  
 Coronary artery disease, 1595  
 Cosegregation, 1068  
 Counterregulatory hormone response, 81, 526, 901, 1531, 1608  
 Crinophagy, 309  
 Cross-linking and aging, 867  
 CSII. See Continuous subcutaneous insulin infusion (CSII)  
 CS-045, 1549  
 Cyclohexamide, 1426  
 Cyclophosphamide, 930, 1722  
 Cyclosporin A, 873, 1049, 1305, 1574  
 Cyclo(His-Pro), 1120  
 Cytochrome *P*-450, 577  
 Cytokines, 133  
 Cytotoxicity, 133  
 C-peptide  
   concentrations, 1353  
   kinetics, 223  
   response to glucagon, 99  
   secretion, 590, 920

**D**  
 Dawn phenomenon, 166  
 Depolarization of glucose-induced  $\beta$ -cell, 495  
 Diabetic foot, 714  
 Diacylglycerol, activator of protein kinase C, 3, 499  
 1,2-Diacylglycerol, 1168  
 Diuresis, 949  
 DNA damage, 1015

Dogs  
   adenosine and myocardial insulin responsiveness, 842  
   amino acid infusion, 237  
    $\beta$ -Cell loss indicator, 723  
   chronic diabetes effects, 943  
   depancreatized, 600  
   endogenous glucose production, 1025  
   gluconeogenesis role, 749  
   microvascular perfusion, 1715T  
   myocardial metabolism, 943, 1684  
   partially pancreatectomized, 723  
   purified islets, 467  
 Dopamine, 956  
 DR1/4 patients, 926  
 DR3/4 patients, 926  
 Drug metabolism, cytochrome *P*-450, 577

**E**  
 Eicosanoids, 367  
 ELISA. See Enzyme-linked immunosorbent assay (ELISA)  
 Embryogenesis, 585, 637, 974  
 Embryopathy, 974  
 Endocrine growth, 232  
 Endocrine Society, 1449  
 Endogenous glucose production rate, 154, 1025  
 Endogenous opioid peptides, 1253  
 $\beta$ -Endorphin, 1265  
 Endothelium, 261  
 Endothelial cells  
   adherence of erythrocytes, 104  
   factor VIII antigenicity, 482  
 Endotoxin, synergistic effects, 112  
 Environmental perturbants, 258  
 Enzyme-linked immunosorbent assay (ELISA)  
   islet cell antigens, 1137  
   measurement of rat insulin, 321  
 Enzyme inhibition, 89  
 Epinephrine  
   hypoglycemia, 901  
   insulin absorption, 694  
   insulin secretion, 65  
 Epstein-Barr virus, 982  
 Erythrocytes  
   acylation of phosphatidylcholine, 142  
   adherence to endothelial cells, 104  
   charge and microalbuminuria, 745  
   deformity, 471  
   viscosity, 471  
 Ethanol, 912  
 Ethiopian immigrants, prevalence of diabetes, 824  
 Ethnic groups  
   Canadian children, 1096  
   geographic patterns, 1113  
   Israelis, 297  
   Ethiopian immigrants, 824  
   Japanese, 1068, 1633

Mexican Americans, 878  
 Pima Indians, 60, 622  
 Etiology of diabetes, 257, 1328, 1625  
 Etomoxir, 28  
 Exocrine  
   growth, 232  
   secretion, 1173  
 Exocytosis, 194  
 Exon, human glucose-transporter gene, 657

**F**  
 Factor VIII, 482  
 Familial diabetes. See Genetics  
 Fasting, synergistic effects, 112  
 Fatty acid synthesis, 50  
 Feet. See Diabetic foot  
 Fish oil, 1567  
 Free fatty acids  
   dawn phenomenon, 166  
   early prandial insulin secretion, 736  
   hypoglycemic effects of modifying drugs, 28  
   insulin secretion, 1595  
   insulin's antilipolytic effect, index of, 1271  
   measurement, 1020  
 Fruit flies, 847

**G**  
 Galactose cataracts, 1505  
 Galanin, 1157  
 Gangliosides, 645, 1340  
 Gastric inhibitory polypeptide, 200  
 Genes. See Genetics  
 Genetics, 663  
   analysis, 377, 569, 707  
    $\beta$ -Chain, 1633  
   elements, 257  
   human glucose-transporter gene, 657  
   insulin Wakayama, 862  
   Japanese, 1633  
   mice, 707, 1163  
   nucleotide substitution, 1068  
   perinatal mortality, 1328  
   organ-reactive autoantibodies, 1287  
   susceptibility gene, 1005, 1438  
   T-lymphocyte alterations, 1484  
 Gestational diabetes, 377  
 Glibenclamide. See Glyburide  
 Glomerular  
   barrier, 1202  
   basement membrane, 532, 1144, 1324  
   charge, 745  
   deposits, 185  
   filtration rate, 1044, 1641  
   morphology, 38  
   Na<sup>+</sup>-K<sup>+</sup>-ATPase, 558  
 Glomeruli, 429  
 Glomerulopathy, 38, 1202

**DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE**

January, 1-136	April, 367-493	July, 847-1004	October, 1311-1448
February, 137-255	May, 495-665	August, 1005-1156	November, 1449-1590
March, 257-365	June, 667-845	September, 1157-1309	December, 1591-1726

**SUBJECT INDEX 1988**

- Glucagon  
 β-Endorphin effects, 1265  
 immunoreactivity, 81  
 early prandial insulin secretion, 736  
 growth hormone effects, 1678  
 islet cell tumors, 1647  
 secretion  
   galanin effects, 1157  
   pancreastatin effects, 281  
   sodium butyrate effects, 1405
- Glucokinase, 563, 1524
- Gluconeogenesis, 749
- Glucose  
 β-Endorphin effects, 1265  
 cellular pathways, 421  
 concentration, 1559  
 control  
   counterregulatory hormone response, 526  
   pancreatic β-cells, 81  
 insulin response, 286  
 intolerance, age-related, 119  
 intracellular free, 885  
 measurement, 1020  
 metabolism, 237, 563, 1226, 1426, 1470, 1524  
 normalization of levels, 1689  
 oxidation, 912, 916  
 pantothenic acid uptake, 1335  
 phosphoinositide hydrolysis, 1294  
 recycling, 154  
 thresholds, 901  
 tolerance  
   genetic analysis, 707  
   impaired, 824, 1595  
   intra-arterial test, 441  
   myocardial uptake,  
 toxicity, 681  
 transport  
   effect of phorbol esters, 499  
   human glucose-transporter gene, 657, 1583  
   inhibition of, 1217  
   skeletal muscle glucose metabolism, 885  
 turnover, taste-induced changes, 773  
 usage, 563
- Glucose-induced insulin secretion, 217, 367, 398
- Glucose-induced diabetes, 600
- Glyburide, 857, 1090
- Glyceraldehyde phosphate, 997
- Glycogen  
 metabolism, 262  
 placental, 1665  
 synthase, 436  
 synthesis, 303, 499, 1559
- Glycolysis, 303
- Glycolytic intermediate, 997
- Glycosaminoglycans, 745, 1324
- Glycosylated  
 hemoglobin  
   level of and blood flow, 292  
   oral glucose tolerance test, comparison, 60  
   insulin, 787  
   low-density lipoprotein, 550, 1652  
 Golgi fractions, cAMP phosphodiesterase activity, 717  
 Growth hormone, 166, 1678
- H**
- HbA<sub>1c</sub>. See Glycosylated hemoglobin
- Heart  
 adenine nucleotide metabolism, 629  
 L-carnitine treatment effects, 1358  
 dysfunction, 936
- Heparan sulfate, 1324
- Heparin, 610, 1103
- Hepatic  
 glucose  
   output, 119  
   production, 667, 1020, 1470, 1531  
   uptake, 1559  
 insulin secretion, 223  
 surface receptors, 1316  
 triglyceride lipase, 610
- Hepatocytes, 806, 1234, 1316
- Hexokinase, 563, 1524
- High-fat diet, 1397
- High-molecular-weight aggregates, 56
- HIT cells, insulin biosynthesis, 160, 1509
- HLA antigens, 796  
 HLA-DQw3(TA10<sup>-</sup>), 926  
 HLA-DR antigens, 99  
 insulin-dependent diabetes, 1005
- Human  
 fetal isletlike cell clusters, 1678  
 fetal/neonatal development, 286  
 glucose-transporter gene, 657  
 insulin, 276  
 insulinoma cells, 1279  
 insulin-receptor gene, 1241  
 islets, 413, 992  
 mononuclear leukocytes, 1386  
 See also Proinsulin
- Hydrochlorides, 540
- Hydroxyl radical scavengers, 1015
- Hyperglucagonemia, 44
- Hyperglycemia  
 acquired, 1035  
 brain striatum changes, 1120  
 clonidine-induced, 44  
 fasting, 673  
 glucose-induced diabetes, 600  
 L-carnitine treatment effects, 1358  
 pain perception, 1253  
 prandial, 736  
 transient, 89
- Hyperimmunoglobulinemia A, 177
- Hyperinsulinemia, 1212
- Hyperlipidemia, 342, 1618
- Hypertension, 1595
- Hypertriglyceridemia, 832, 1271
- Hypoglycemia  
 cerebral metabolism, 760  
 counterregulatory hormone response, 526, 901, 1531, 1608  
 gluconeogenesis role, 749  
 -hypoinsulinemic effect, 1618  
 insulin induced, 81, 760, 1531  
 Hypothalamus, regulatory peptides, 763
- I**
- IDDM. See Insulin-dependent diabetes mellitus
- IgG proinsulin autoantibodies, 130
- Immune  
 complexes, 185  
 process, precursors of insulin, 130  
 reactions, streptozocin-specific, 74  
 regulation, 1009  
 system role, 520
- Immunoglobulin A, elevated levels, 177, 185
- Immunology, 257, 662
- Incretin, 200
- Inflammatory mediators, 112
- Insulin  
 absorption and epinephrine, 694  
 action, 262, 540  
 adipocyte metabolism, 912  
 aggregates, 56, 1059  
 alveolar macrophages, 544  
 antibodies, 276, 920, 1049  
 antilipolytic effect, 1271  
 autoantibodies, 317, 1392  
 binding, bacitracin effect on, 800  
 biosynthesis, 160, 309, 1226, 1509, 1678  
 bone cell metabolism, 33  
 cAMP phosphodiesterase activity, 717  
 cephalic, 773  
 clearance, 200, 1351  
 covalent aggregates, 1059  
 deficiency  
   cholesterol, 1151  
   macrophages, 544, 1076  
 dimers, 56  
 euglycemia, 723  
 gene, 569  
 glucoregulatory effect, 1271  
 glucose-transporter gene expression, 1583  
 glycosylated, 787  
 growth factor, 585  
 human, 276  
 hydrochloride salt effect, 540  
 immunity, 172  
 immunotherapy agents, 1188  
 in vitro, 421, 780, 787  
 in vivo, 421, 456, 780  
 incretin effect, 200  
 infusion  
   counterregulatory hormone response, 526

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1–136	April, 367–493	July, 847–1004	October, 1311–1448
February, 137–255	May, 495–665	August, 1005–1156	November, 1449–1590
March, 257–365	June, 667–845	September, 1157–1309	December, 1591–1726

**SUBJECT INDEX 1988**

- gluconeogenesis role, 749  
intensive therapy, 393, 901  
islet cell tumors, 1647  
kinetics, 223  
leucine metabolism, effect on, 512  
  mediator, 262  
low-density lipoprotein–receptor activity, 1386  
measurement, 1020  
monomeric, 56  
mutant allele, 1068  
NPH, 172  
oral administration, 246  
pantothenic acid uptake, 1335  
parotidectomy, effect of, 443  
platelet function, 780  
precursors of, 130  
pulse, 1316  
radioimmunoassay, 1392  
receptors  
  alterations, 33  
  autophosphorylation, 1397  
  binding, 56, 262, 585, 1515  
  cephalic phase, 773  
  developmental regulation, 637  
  gene, 377, 1071, 1241  
  internalization, 806  
  kinase activity, 262, 1397  
  phosphorylation, 147  
  proreceptor cleavage failure, 653  
  pulses of insulin, 1316  
  structure defects, 982  
resistance  
  cellular mechanisms, 677  
  glucose transport, 1217  
  hepatic glucose production, 1470  
  high-fat diet effects, 1397  
  in vitro, 421  
  in vivo, 421  
  leprechaunism, 982  
  lipid oxidation role, 678  
  maturity-onset diabetes of the young, 730  
  myocardial metabolism, 843, 943, 1684  
  non-insulin-dependent diabetes factor, 667, 1595  
  oral antidiabetic agent, 1549  
  phosphorylation, 147  
  proreceptor cleavage failure, 653  
  restriction-fragment-length polymorphism, 1071  
  site of, 670  
  summary, 672  
retroviral antigen p73, 351  
secretion  
  acute insulin responses, 723  
  arachidonate metabolites, 992  
  cAMP influence, 1478  
  cholecystokinin effects, 1432  
  cyclosporin effects, 1574  
  diminished, non-insulin-dependent diabetes factor, 667, 674  
  early prandial, 736  
  eicosanoids, 367  
   $\beta$ -Endorphin-induced effects, 1265  
  epinephrine effects, 65  
  fetal development, 286  
  galanin effects, 1157  
  glucose concentration changes, 309  
  glucose metabolism, 1226  
  increased, 200, 1351  
  integrated serum values, 590  
  interleukin 1, 916, 1311  
  intermediary metabolites, 997  
  maturity-onset diabetes of the young, 730  
  measuring, 223, 1195  
  mononuclear cells, 873  
  pancreastatin effects, 281  
  parotid glands, 441  
  phosphoinositides hydrolysis, 1294  
  protein kinase C, 3, 1453  
  residual significance, 81  
  response, 137, 217, 286  
  reversible impairment, 398  
  sulfonylureas, 847  
  tolbutamide effects, 816  
sensitivity  
  chronic diabetes effect, 943  
  gestational diabetes, 377  
  non-insulin-dependent diabetes, 669  
  phorbol esters, 499  
  vascular smooth muscle cells, 1380  
sodium butyrate effects, 1405  
-stimulated adipocyte lipogenesis, 912  
subcutaneously injected, 694  
treatment  
  cytochrome *P*-450, 577  
  IgG autoantibodies, 130  
  nephropathy, effects on, 1346  
  1,2-diacylglycerol, 1168  
  vanadate, mimetic effects, 1234  
  vasodilator action, 1064  
  Wakayama, 862, 1068  
Insulinoma, 563, 1279  
Insulin-dependent diabetes mellitus  
  activated T-lymphocytes, 507, 792  
  autonomic and somatosensory nerve function, 452  
  bone mineral content, 8  
  breast feeding, 1625  
  Canadian children, 1096  
  cardiac function, 851  
 $\beta$ -cell  
  destruction, 133, 930  
  survival, predictors of, 920  
class I heavy-chain gene expression, 1411  
cyclosporin A, 1049, 1574  
etiology, 1328  
geographic patterns, 1113  
glycemic thresholds, 901  
high-molecular-weight aggregates, 56  
HLA, 1005  
HLA-DQw3(TA10<sup>-</sup>), 926  
IgG proinsulin antibodies, 130  
insulinitis pathogenesis, 204  
intensive therapy and low-density lipoproteins, 393  
interleukin 1, 916  
lung volumes reduced, 829  
neonatal, 347  
neuropathy, 476  
oral administration of insulin, 246  
prediction, 1591  
recent-onset, antibodies, 462  
remission, 1574  
renal hemodynamics, 1044  
stress and insulin absorption, 694  
T-lymphocyte alterations, 1484  
vascular dysfunction, 292  
vitamin E supplementation, 1260  
Insulin-like growth factor, 637, 1515, 1678, 1689, 1708  
Insulinitis, 260  
  endogenous retrovirus, 1722  
  macrophage involvement, 989, 1053  
  pathogenesis of, 204  
  progression to  $\beta$ -cell destruction, 1108  
  protected rats, 1009  
  single-cell, 21  
  streptozocin induced, 1373  
Intensive treatment and low-density lipoproteins, 393  
Interferon- $\gamma$ , 133, 209  
Interleukin 1, 916, 1311  
Interleukin 2  
  adoptive immunotherapy, 1305  
  islet cell cytotoxicity, 133  
Intracellular  
  hormone degradation, 194  
  killing and alveolar macrophages, 544  
Intrauterine environment, 622  
Ion channels, 847  
Islets  
  cell antibodies, 99, 347, 645, 664  
  cell antigens, 1137, 1287, 1587  
  cell tumors, 1647  
  cholecystokinin effects, 1432  
  destruction by cytokines, 133  
  endothelial cells, 482  
  function studies, 723  
  macrophage infiltration, 21  
  neogenesis, 891  
  phosphatidylcholine, 1489  
  protein kinase C characteristics, 3  
  regeneration, 334  
  secretion, 1316  
  See also Pancreatic, islets  
Islets of Langerhans  
  pancreatic polarity of  $\beta$ -Cell, 616  
  transplantation, 467  
Isotope discrimination, 1025  
Israel, prevalence of diabetes, 297  
  Ethiopian immigrants, 824
- J**  
Japan  
  abnormal insulinemia, 1068

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1–136	April, 367–493	July, 847–1004	October, 1311–1448
February, 137–255	May, 495–665	August, 1005–1156	November, 1449–1590
March, 257–365	June, 667–845	September, 1157–1309	December, 1591–1726

**SUBJECT INDEX 1988**

genetics, 1633  
Junctional coupling, 908

**K**

K<sup>+</sup> channels, 495  
Ketoacidosis, 1470  
Ketogenesis, 50  
Kidney  
  cells, bacitracin effect on, 800  
  transplantation, 1247  
Kinase, 262

**L**

Lactate measurement, 1020, 1559  
Laminin, basement membranes, 532  
LDL. *See* Lipoprotein, low-density  
Leg tissue, 1365  
Leprechaunism, 982, 1515  
Leucine  
  flux measurement, 1365  
  insulin effect on metabolism, 512  
Linkage analysis, 569  
Lipids, L-carnitine treatment effects, 1358  
Lipoatrophic diabetes, 421  
Lipogenesis, 50, 912  
Lipoprotein  
  lipase, 610, 1076  
  low density  
    fish oil effect, 1567  
    metabolism, 393, 550  
    platelet aggregation, 1652  
    -receptor activity, 1386  
Liposomes, 1123  
Lipoxygenase, 65, 992  
Liver Golgi fractions, 717  
Lung volumes, 829  
Lymphopenia, 327  
Lymphoproliferation, 74  
Lymphotoxin, islet cell cytotoxicity, 133  
Lysosomes  
  bacitracin effects, 800  
  pancreatic islet function, 309

**M**

Macrophage  
  alveolar, 544  
  high-affinity receptor, 456  
  human, 550  
  infiltration in islets, 21  
  insulinitis development, 989, 1053  
  lipoprotein lipase, 1076  
  pathogenesis of insulin-dependent diabetes, 1301  
  peritoneal, 456  
Major histocompatibility complex (MHC)  
  class I antigens

heavy-chain gene expression, 1411  
  proteins, 362  
class II antigens, 209, 482, 1373, 1637  
reovirus infection, 362  
susceptibility  
  gene, 1438  
  resistance to diabetes, 520  
Mannoheptulose, 1426  
Marrow transfer, 252  
Mathematical modeling, 223, 1025  
Maturity-onset diabetes of the young (MODY), 730  
MEDICA 16, 1618  
Mesangial sclerosis, 1695  
Mesenchyme, 891  
Messenger RNA, human glucose-transporter gene, 657  
Mexican Americans, retinopathy, 878  
Mice  
  β-cell granules morphometry, 194  
  coxsackievirus B4 infection, 1419  
  diet-induced obesity, 1163  
  embryos, binding to, 585  
  genetics, 707, 1287  
  glucose tolerance, 707  
  lipoprotein lipase, 1076  
  nonobese diabetic (NOD)  
    adoptive immunotherapy, 1305  
    autoantibodies, 1587  
    β-cell destruction, 930, 1108  
    insulin and retroviral antigen p73, 351  
    insulinitis, 204, 989, 1722  
    marrow transfer, 252  
    phospholipid metabolism, T-lymphocyte clone, 1444  
    oral antidiabetic agent, 1549  
    pancreastatin effects, 281  
    transient hyperglycemia, 89  
    T-lymphocyte depletion, 1082  
  *See also* Streptozocin-induced diabetes  
Microalbuminuria, 745  
Microvascular  
  disease, 851  
  perfusion, 1715  
Mixed meal, 436, 512  
Monoclonal antibodies, 462, 1082, 1108, 1137  
Mononuclear  
  cells, 832, 873  
  leukocytes, 1386  
Morphine, 1253  
Motor nerve conduction, 1247  
Muscle  
  glucose metabolism, 667  
  skeletal  
    glycogen and mixed-meal, 436  
    phorbol esters effects, 499  
*myo*-Inositol  
  myocardial lipids and cardiac function, 1542  
  neuroectodermal tissue, 974  
  neuropathy pathogenesis, 688  
Myocardial  
  contractility, 851

glucose uptake, 842  
lipids, 1168, 1542  
metabolism, 943, 1684

**N**

Na<sup>+</sup>-K<sup>+</sup> pump, insulin stimulation, 33  
Na<sup>+</sup>-K<sup>+</sup>-ATPase, 558  
  neuropathy pathogenesis, 688  
  sciatic nerve abnormalities, 1340  
Nanocapsules, 246  
Nationwide Comprehensive Long-Range Plan, 1449  
Natural killer cells, 838  
Neonatal diabetes, 347  
Nephropathy  
  activated T-lymphocytes, 507  
  cardiac function, 851  
  erythrocyte charge, 736  
  insulin therapy effects, 1346  
  low-protein diet, 1641  
  mesangial sclerosis, 1695  
  Nerve conduction velocity, 969  
Nesidioblastosis, 334  
Neuroectodermal tissue, 974  
Neuropathy  
  aldose reductase inhibition, 969  
  autonomic  
    abnormal thermoregulation, 961  
    diuresis, 949  
  development factors, 476  
  painful, 1253  
  pancreatic islet cell allotransplantation, 1129  
  pathogenesis, 688  
  phospholipid metabolism, 1703  
  pupillary unrest, 446  
  *See also* Polyneuropathy  
Neuropeptide Y, 763  
Nicotinic acid, additive hypoglycemic effects, 28  
Nonenzymatic glycosylation, 456, 532, 867, 1103, 1144  
Nonimmunosuppressive immunomodulator, 1188  
Nonobese diabetic mice. *See* Mice  
Non-insulin-dependent diabetes mellitus  
  β-cell destruction markers, 99  
  day-long hypoinsulinemia, 590  
  familial, 377, 569  
  fish oil effect, 1567  
  genetic model, 398  
  glomerulopathy, 38  
  HLA antigens, 796  
  insulin resistance, 667, 1071, 1595  
  insulin secretion  
    diminished, 667  
    early prandial, 736  
  intrauterine environment, 622  
  Mexican Americans, 878  
  mixed-meal ingestion, 436  
  obesity, 154, 1163  
  pathogenesis, 679

Downloaded from <http://diabetesjournals.org/diabetes/article-pdf/37/12/1727/355827/37-12-1727.pdf> by guest on 14 July 2024

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1–136	April, 367–493	July, 847–1004	October, 1311–1448
February, 137–255	May, 495–665	August, 1005–1156	November, 1449–1590
March, 257–365	June, 667–845	September, 1157–1309	December, 1591–1726

**SUBJECT INDEX 1988**

proteinuria, 405, 1499  
 screening, 60  
 Norepinephrine, 1064  
 Normoglycemia, 467  
 5'-Nucleotidase, 629  
 Nucleotide substitution, 1068

**O**

**Obesity**  
 diet induced, 1163  
 increased rate of Cori cycle, 154  
 organ-reactive autoantibodies, 1287  
 taste-induced changes, 773  
**Opossum, bacitracin effect, 800**  
**Oral antidiabetic agent, 1549**  
**Oral glucose tolerance test, 60**  
**Organ-reactive autoantibodies, 1287**  
**Osteoblasts, insulin receptors, 33**  
**Osteopenia**  
 markers, 702  
 measurement, 8  
**Oxidation, 678, 1212, 1226**

**P**

**Painful neuropathy, 1253**  
**Pancreas**  
 bovine, 1137  
 ductal epithelium, 891  
 human, 286, 1137  
 macrophage subpopulations, 1301  
 murine, 1373  
 perfusion, 398  
**Pancreastatin, 281**  
**Pancreatectomy, partial, 232, 723**  
**Pancreatic**  
 acini, 13  
 ductal epithelium, 891  
 endocrine cells, 383  
 islets  
 antigen, T-lymphocyte clone, 1444  
 cell allotransplantation and  
 neuropathy, 1129  
 cellular perfusion, 1715  
 class I heavy-chain gene expression,  
 1411  
 eicosanoids, 367  
 insulin production, 1226  
 insulin secretion, 992  
 interleukin 1, 916  
 isolation of, 413  
 liposomes, 1123  
 lysosomes, 309  
 neuropathy and allogeneic  
 transplantation, 1129  
 phosphatidylcholine, 1489  
 pregnancy, 908  
 proinsulin conversion, 1426  
 tolbutamide effects, 816  
 nonislet autoantibodies, 347  
 polarity, 616  
 remnants, 232

Pantothenic acid uptake, 1335  
 Parotid glands, 441  
 Paternal transmission, 1035  
 Peripheral glucose metabolism, 119  
 Perfusion, tolbutamide effects, 816  
 Perinatal mortality, 1328  
 Phagocytosis and alveolar macrophages,  
 544  
 Phorbol esters, effects on skeletal muscle,  
 499  
 Phosphatidylcholine, 142, 1489  
 Phosphodiesterase, cAMP activity, 717  
 Phosphofructokinase, 1524  
 Phosphoinositides  
 cholecystokinin effects, 1432  
 hydrolysis, 1294  
 insulin secretory response, 137  
 neuropathy pathogenesis, 688  
 tolbutamide effects, 816  
 Phospholipase A<sub>2</sub>, 429, 1489  
 Phospholipase C, 429  
 Phospholipids  
 acylation, 142  
 1,2-diacylglycerol, 1168  
 metabolism, 1703  
 organization alterations, 104  
 Phosphorylation, 147, 262, 1703  
 Pima Indians, 60, 622  
 Plasma lipolytic activity, 610  
**Platelet**  
 aggregation, 1652  
 insulin influence, 780  
 thromboxane A<sub>2</sub>, 1260  
 Polyalkylcyanoacrylates, 246  
 Polygenic inheritance, 707  
 Polymerase chain reaction, 862  
 Polymorphism, 1068  
 restriction-fragment-length  
 polymorphisms, 377, 569, 1071  
 Polyneuropathy, 1000, 1247  
 Polyol pathway  
 abnormalities and ascorbic acid, 359  
 increased flux, 471  
 Poly(ADP-ribose) synthetase, 213  
 inhibitors, 1015  
 Pregnancy, 908, 1328, 1665, 1671  
 Prevalence  
 Israel, 297  
 Ethiopian immigrants, 824  
 Mexican Americans, 878  
 Pima Indians, 622  
 Prevention of diabetes, 327, 1009, 1188,  
 1591  
 Primary postbinding defects, 421  
 Professional vs. volunteer organization,  
 1449  
**Proinsulin**  
 antibody, 276  
 conversion process, 1426  
 glucose-stimulated biosynthesis, 160,  
 1509  
 human immunogenicity, 276  
 IgG autoantibodies, 130  
 therapy, 276

**Promoter region**  
 human glucose-transporter gene, 657  
 human insulin-receptor gene, 1241  
 Proreceptor cleavage failure, 653  
 Prostaglandins, 429, 992, 1044  
 Protamines, 172  
 Protein degradation, 1665, 1671  
**Protein kinase C**  
 insulin secretion, 3, 1453  
 skeletal muscle, 499  
 cAMP dependent, 857  
**Proteinuria**  
 activated T-lymphocytes, 507  
 charge selectivity in glomerulopathy,  
 1202  
 effect on mortality, 1499  
 epidemiology of, 405  
 low-protein diet, 1641  
 Proteolysis, 512, 1365  
 Pupillary unrest, 446

**R**

Rabbit, femoral artery, 1064  
**Rats**  
 additive hypoglycemic effects of drugs,  
 28  
 alloxan-induced diabetes, 1173, 1340  
**BB**  
 alveolar macrophages, 544  
 class I heavy-chain gene expression,  
 1411  
 class II genes, 1637  
 diabetes prevention, 327, 1009, 1188  
 insulinitis and macrophages, 1053  
 recurrent autoimmune diabetes,  
 prevention of, 838  
 vascular smooth muscle cells, 1380  
 BB/E, macrophage subpopulations,  
 1301  
**BB/W**  
 adenine nucleotide metabolism in  
 hearts, 629  
 immune system role, 520  
 cAMP phosphodiesterase activity, 717  
 L-carnitine treatment effects, 1358  
 cataractogenesis, 1505  
 β-cell secretory responses, 217  
 corpulent, 398  
 collagen production, 371  
 fasting, clonidine effects, 44  
 hepatic glucose uptake, 1559  
 hepatocytes, 1316  
 hypothalamic concentrations, 763  
 insulin  
 biosynthesis, 1509  
 glucose-induced secretion, 398  
 hydrochloride salt effect, 540  
 measurement, 321  
 receptor internalization, 806  
 stimulation of Na<sup>+</sup>-K<sup>+</sup> pump, 33  
 insulintropic effect, 441

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1–136	April, 367–493	July, 847–1004	October, 1311–1448
February, 137–255	May, 495–665	August, 1005–1156	November, 1449–1590
March, 257–365	June, 667–845	September, 1157–1309	December, 1591–1726

**SUBJECT INDEX 1988**

- liver  
 perfusion, 50  
 sulfonyleurea effect, 857  
 major histocompatibility complex genes, 1438  
 nephropathy, insulin therapy effects, 1346  
 neuroectodermal tissue, 974  
 neuropathy and allogeneic islet cell transplantation, 1129  
 pancreatotomy, 232  
 pancreatic  
 acini, 13  
 $\beta$ -cells and sulfonyleureas, 1090  
 islets, 133, 413, 816, 908, 916, 1453, 1478  
 perfused working hearts, 1335  
 pregnancy, 908, 1665, 1671  
 prostaglandin synthesis, 429  
 reovirus infection, 362  
 sand, 1618  
 skeletal muscle, 499  
 taste-induced changes, 773  
 urinary bladder, 949  
 See also Streptozocin-induced diabetes
- Receptors. See Insulin, receptors  
 Recurrent autoimmune diabetes, 838  
 Regulatory peptides, 763  
 Renal hemodynamics, 1045  
 Reovirus infection, 362  
 Resistance to ischemic block conduction, 969, 1633  
 Restriction-fragment-length polymorphisms (RFLPs), 377, 569, 1071, 1633  
 Retinopathy, 878, 1658  
 Retrovirus  
 insulinitis, 1722  
 retroviral antigen p73 and insulin, 351
- S**  
 Saccharin ingestion and taste-induced changes, 773  
 Sciatic nerve abnormalities, 1340  
 Screening methods, 60  
 Second-messenger molecules, 137  
 Secretin, 1173  
 Sensory nerve function after CSII, 452  
 Serotonin, 956  
 Serum factor, 1217  
 Sialic acid, 745  
 Silica particles, 21, 930  
 Single-cell insulinitis, 21  
 Skeletal muscle  
 glucose transport, 885  
 glycogen and mixed meal, 436  
 phorbol ester effects, 499  
 Sodium butyrate, 1405  
 Somatostatin  
 clonidine-induced hyperglycemia, 44  
 galanin effects on secretion, 1157  
 islet cell tumors,  
 receptors, 847  
 Superoxide production by mononuclear cells, 832  
 Suppressor/cytotoxic cells, 1484  
 Sympathetic nervous system, 949, 1157  
 Syrian golden hamster, 334
- T**  
 Thermoregulation, 961  
 Thromboxane B<sub>2</sub>, 780  
 Thyrogastric antibodies, 99  
 Thyroid. See Autoimmune thyroid disease  
 Thyrotropin-releasing hormone, 1120  
 Tolbutamide, 816, 857  
 Transcutaneous oxygen tension, 714  
 Triglycerides, 832, 1271  
 L-Tryptophan, 956  
 Tumor necrosis factor, 133  
 Type I diabetes. See Insulin-dependent diabetes mellitus  
 Type II diabetes. See Non-insulin-dependent diabetes mellitus  
 Tyrosine kinase activity, 147  
 T-lymphocytes  
 activated, 507, 792  
 alterations in insulin-dependent diabetes, 1484  
 CD4<sup>+</sup>, 1444  
 depletion, 1082  
 Lyt2<sup>+</sup>, 930  
 L3T4<sup>+</sup>, 204, 1108  
 receptor, 1633
- U**  
 Urea nitrogen pool, 1212  
 Urinary  
 albumin concentration and glomerulopathy, 38, 41  
 bladder, 949  
 C-peptide, 590, 1195  
 excretion, 1044  
 Utah Mormons, 569
- V**  
 Vanadate, 1234  
 Vascular  
 dysfunction, 292  
 permeability, 1689  
 smooth muscle cells, 1380  
 Vasodilator action, 1064  
 Verapamil, 936  
 Vitamin E supplementation, 1260
- W**  
 Weight reduction and Cori cycle, 154

**DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE**

January, 1–136	April, 367–493	July, 847–1004	October, 1311–1448
February, 137–255	May, 495–665	August, 1005–1156	November, 1449–1590
March, 257–365	June, 667–845	September, 1157–1309	December, 1591–1726